A retrospective, real-world study of effect of immune checkpoint inhibitors on survival in Stage IV NSCLC patients
Latest Information Update: 10 Mar 2021
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Mar 2021 New trial record
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer